Drugs: A tangled web of targets
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Researchers have explored inhibiting BACE1 as an alternative to γ-secretase inhibitors due to its higher selectivity for APP, aiming to reduce Aβ production.
“Researchers have explored inhibiting β-secretase (BACE1) as an alternative to γ-secretase inhibitors due to its higher selectivity for APP, aiming to reduce Aβ production.443”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [443]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 5 · Cited by 81
- Authors
- Gravitz, L.
- Corresponding author
- Gravitz, Lauren
- Venue
- Nature
- Published
- 2011-07
- Volume
- 475
- Issue
- 7355
- Pages
- S9-S11
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1964343563
- Cited by
- 81
- References
- 5
- Citations by year
- 2026: 4 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 6 · 2020: 2 · 2019: 6 · 2018: 4 · 2017: 1 · 2016: 3 · 2015: 7 · 2014: 4 · 2013: 16 · 2012: 17
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, drug development, therapeutic target, neurodegeneration
- MeSH terms
- Alanine, Alzheimer Disease, Animals, Antibodies, Monoclonal, Azepines, Clinical Trials as Topic, Humans, Indoles, Memantine, Methylene Blue, Phosphorylation, Genetic Therapy, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Disease Progression, Nerve Growth Factor, Glycogen Synthase Kinase 3, Amyloid Precursor Protein Secretases, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
